you, joining Good for Thank us today. everyone. you afternoon, David. Thank
XXXX and our a milestones revenue revenue company, to Our force, an exciting strong million $XX sequential of the for fourth product XXXX in productive Eton. us in helped than are which XXXX. $XX quarter sales more delivered capped of XXX% accomplishments expansion and off straight including of from critical XXth for XXXX growth internal the our grow and million number brought
to two, year from approve Nitisinone, of products X of Number the the year. start Betaine us the launch by of which commercial the brought commercial and acquisition of products the at end
year. the our the operating advancement in ET and through cash ET positive the development And half acquisition boosted reached XXX. pipeline of second We we also of of the lastly, XXX flow
year X% while XXX% was our attractive $X.X discipline year-over-year. over and leverage business. G&A results. expenses to Turning the an million, Revenue only our quarter increase in fourth demonstrating operating the financial grew the of quarter, prior specific
without growth ALKINDI once in allow current report we reach that us products was continued positive steady GAAP any benefit cash positive of again operating at to another to some flow. the commercial I'm acquisitions, SPRINKLE expect XXXX. delivered quarter fourth our in quarter net the income the Even quarter. of pleased also future to point growth
this of the many years have portion from X,XXX continue We to the patients continue small still can the come of we estimated adrenal converted only XX a who United under to believe as in age insufficiency States. suffer for growth
physician. already to just converting demand start diagnosed to We've a We February. of patients went which growth can immediately the Pediatric our able on are our strong offices and now program, expect hoping that so are boost we seen from positive with physicians a therapy requesting or have live growth. SPRINKLE sampling of in the stock endocrinology their newly to rate samples, XXXX samples program presence in impact a the ALKINDI
remains do and ahead now continues Turning our Carglumic also expectations. acid carglumic to well acid. of initial to
the first have We have the carglumic patient while captured a in over already of is quarter we just to new believe over expected, a XX% higher fourth X in years conversions XXXX. number acid this and than we we patients share additional quarter for in the see continued of market already
So has company we the another and understandably the support year-over-year XXXX deemphasized and promotion carglumic to year for for predict be attractive that It expect growth continue offers brand acid. will its it product. of
in well patient to positioned with are the So we we physician the our and market. continued believe product be support, leading
competitive faces due market and adoption the interactions continues The now potential increased full was see of addition, to more quarter pressure acid it have opportunity carglumic much entrenchment that is Nitisinone market the to Betaine among environment. fourth our smaller prescribers. overall betaine patients. on growing than and and reimbursement carglumic market. further Betaine's quarter and of In launch the second with The
valuable treats a on allow acid and prescriptions. The condition to that its contributor it's within carglumic estimated metabolic launched this that door annually patient been capsules. So to to market. an support $XX to existing XXX Nitisinone share in in services and take lead estimated revenue initiate believe space, third million the be Last get not a market we geneticists impact to a XXX Nitisinone with the United us it's can discussions but the Nitisinone importantly, current of is patients around metabolic to tool tyrosinemia month, ultra-rare major and our is for own, meaningful the States. we annually, relationships our will more product us
few We've already launch. added weeks a number patients within first of the of active
the commercial performance, the to pipeline. our positive recent with X weeks. had we In have I pleased in progress clinical am strong recent addition We seen with development
am to XXX, that bioequivalency pleased data today pivotal passed product on ET the report shows study. preliminary that I First, the
as is You report the to submit year that application hurdle the clinical remember final last our we was plan may NDA submission the NDA so available. soon can this to second study quarter first this now of as in
This would of launch and of half product in first potential the allow a the for approval XXXX.
liquid continue growth highly to and greatly the see We in very ET-XXX in confident formulation years interest come be the and that driver strong major will hydrocortisone to value company. a a remain for our accelerate
Orange office. issued and an on until This cover patent will We formulation. a listable received patents notice February States is product XXXX the under for that we also additional ET-XXX in patent have that Book United review patent with the product currently been we the have proprietary
to Turning now ET-XXX.
its study, study. be the ultra the in study. pivotal given ET-XXX clinical diabetes the targeting file XXXX. about We pivotal pilot saw successful, in the called study second product we're and that optimistic our of second first results is success was now data point that quarter products And we of can this year. this the in bioequivalence the the of is in the we to study run position half has If a pilot report the We to now NDA would The candidate insipidus. rare plan condition on product passed
generic it latest request in resources the dehydrated to the is late but we competitors been would In Eton's Regarding prudent the market unfortunately, potential year, the of additional work. data. FDA's manufacturing require entering additional this undertake of or use collection engaged new have not capital batches, alcohol, it light FDA, additional of seems dialogue with next of stability
on focus potential will with we We feel our significant risk-adjusted programs long-term instead will earnings higher-value resources our better that investments. on returns provide
a but We in the to to to exploring economics investment Eton product company out-license and still opportunities the asset additional the able dehydrated are also the share alcohol of market. not from that allow require is would would the reach transaction
programs, additional existing ET-XXX shortly. ET-XXX, In we of pipeline ZENEO are potential auto-injector, to communicate which hope addition development our and we programs currently to exploring
forward business the we As today, Eton's about rapidly XXXX our started, are proud we getting we continue results as XXXX are discussed and excited we the as beyond. and that is for for potential we year grow just XXXX. to up to look XXXX in we more as be and positioned critical prospects to even launch gear a are ET-XXX
we year, products all significantly. our of grow commercial to This expect
to most expect the notably further pipeline, advance submission NDA. We with our high-value of ET-XXX
add to year. income positive development commercial net expect reach some GAAP and during expect at a we to the activities, We business on through point basis additional products
more all half of of us are and cash the front. very puts hand. remain to on of to deliver cash operating as with development year. second flow on than you in generated financial heard, active positive plans. in these $XX the positioned and business year the well And We capitalized million on position This we a finished We well opportunistic strong the
we that, optimistic detail. the year. We that it and discuss players With continue over many will Chief be many to Officer, on turn this greater capitalize James? I'll the in see increased we to industry, opportunities levels our of in Financial remain distress James, able to results among to financial even
